EU regulator reviewing possible links between Johnson & Johnson jab and blood clots

World

Europe’s drugs regulator is reviewing possible links between blood clots and Johnson & Johnson’s coronavirus vaccine.

It comes after four serious cases of rare clots with low platelets were reported after inoculation, one of which was fatal, according to the European Medicines Agency (EMA).

The Johnson & Johnson (also known as Janssen) vaccine has been rolled out in the European Union and the US in recent months, having proved 67% effective in preventing COVID-19 and completely effective at preventing hospital admissions and death from the virus during trials.

It stands out from the other jabs being used because only one shot is needed, rather than two.

The UK has ordered 30 million doses, but it has not yet been approved by the regulator.

Both the EMA and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) have investigated links between rare clots and the Oxford-AstraZeneca vaccine, but this is the first formal disclosure that the Janssen jab is also being looked into.

Products You May Like

Articles You May Like

BP reports second-quarter profit of £6.9bn – highest in 14 years
Archie Battersbee cannot be moved to hospice to die, High Court rules
UK economy to be in recession for more than a year, Bank of England warns as it hikes rates
‘Fears of new bureaucracy, rules and costs have all come true’: Brexit making touring Europe ‘unviable’ for UK artists
Climate groups react to Senate passing the Inflation Reduction Act

Leave a Reply

Your email address will not be published.